Page last updated: 2024-12-06

triazinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Triazines are heterocyclic compounds containing a six-membered ring with three nitrogen atoms and three carbon atoms. Triazines are important in the field of medicinal chemistry because they are commonly found in herbicides, fungicides, and pharmaceuticals. They are also used as intermediates in the synthesis of other organic compounds. Triazines have been studied extensively for their biological activities, including their ability to inhibit enzyme activity, their antitumor properties, and their potential as insecticides. The synthesis of triazines typically involves the reaction of a carbonyl compound with a hydrazine derivative. The reaction can be catalyzed by an acid or a base. Triazines are highly versatile compounds with many potential applications. They are a valuable tool for medicinal chemists and synthetic organic chemists.'

triazinate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID38777
CHEMBL ID587564
SCHEMBL ID6456167
MeSH IDM0058809

Synonyms (25)

Synonym
ethanesulfonic acid,6-diamino-2,2-dimethyl-1,3,5-triazin-1(2h)-yl)phenoxy]methyl]-n,n-dimethylbenzamide (1:1)
triazinate
nsc-139105
baker's antifol soluble
BAF ,
nsc 139105
tzt ,
nsc139105 ,
41191-04-2
mls002920470 ,
ethanesulfonic acid,6-diamino-2,2-dimethyl-s-triazin-1(2h)-yl)-phenoxy]-n,n-dimethyl-m-toluamide
baker's triazine antifolate
m-toluamide, alpha-(2-chloro-4-(4,6-diamino-2,2-dimethyl-s-triazine-1(2h)-yl)phenoxy)-n,n-dimethyl-, ethanesulfonate
smr001798060
CHEMBL587564
TCMDC-137788 ,
CCG-35419
unii-dd99y262wc
dd99y262wc ,
SCHEMBL6456167
nsc 139105; soluble baker's antifol
3-[[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1-yl)phenoxy]methyl]-n,n-dimethylbenzamide;ethanesulfonic acid
Q27276340
ethanesulfonic acid--3-{[2-chloro-4-(4,6-diimino-2,2-dimethyl-1,3,5-triazinan-1-yl)phenoxy]methyl}-n,n-dimethylbenzamide (1/1)
DTXSID70961492

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"A pharmacokinetic model for triazinate uptake in L-1210 cells in mice and W-256 cells in rats was developed to describe the observed concentration profiles with time in these cells following a 36 mg/m2 ip injection."( In vivo pharmacokinetics of triazinate in L-1210 and W-256 cells.
Cashmore, AR; Jain, RK; Townsend, JG, 1982
)
0.85

Compound-Compound Interactions

ExcerptReferenceRelevance
" Based on the observed objective tumor response rate and median patient survival, further studies of these drugs in combination for the treatment of advanced gastric cancer are indicated."( Phase II clinical trial of triazinate in combination with mitomycin C for patients with advanced gastric cancer.
Hahn, RG; Moertel, CG; O'Connell, MJ; Schutt, AJ, 1987
)
0.57
" They were randomly assigned to receive one of the three drug combination regimens or to 5-FU alone administered by rapid injection in 5-day course."( Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.
Cullinan, SA; Krook, JE; Mailliard, JA; Moertel, CG; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" The dosage utilized was 250 mg/m2 intravenously, administered daily in three consecutive days."( A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma.
Frytak, S; Hahn, RG; McCreary, RH; Moertel, CG; O'Connell, MJ; Reitemeier, RJ; Rubin, J; Schutt, AJ, 1977
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency2.23870.01846.806014.1254AID624417
USP1 protein, partialHomo sapiens (human)Potency3.16230.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency0.09100.000811.382244.6684AID686978; AID686979
67.9K proteinVaccinia virusPotency2.86170.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency0.00820.005210.865235.4813AID686970
VprHuman immunodeficiency virus 1Potency63.09571.584919.626463.0957AID651644
Guanine nucleotide-binding protein GHomo sapiens (human)Potency8.91251.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]Homo sapiens (human)IC50 (µMol)35.84901.15306.28039.9630AID602235
transactivating tegument protein VP16 [Human herpesvirus 1]Human alphaherpesvirus 1 (Herpes simplex virus type 1)IC50 (µMol)35.84900.94604.70169.4870AID602236
nuclear receptor coactivator 3 isoform aHomo sapiens (human)IC50 (µMol)7.47500.14764.33099.9200AID602234
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (84.31)18.7374
1990's2 (3.92)18.2507
2000's2 (3.92)29.6817
2010's3 (5.88)24.3611
2020's1 (1.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.00 (24.57)
Research Supply Index4.30 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (25.86%)5.53%
Reviews3 (5.17%)6.00%
Case Studies1 (1.72%)4.05%
Observational0 (0.00%)0.25%
Other39 (67.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]